Danaher (DHR) Tops Q1 EPS by 26c; initiates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Danaher (DHR) PT Lowered to $260 at JPMorgan
April 22, 2025 1:45 PM EDTJPMorgan analyst Tycho W. Peterson lowered the price target on Danaher (NYSE: DHR) to $260.00 (from $280.00) while maintaining a Overweight rating.
The analyst comments "Like we noted in our first take earlier this morning, 1Q25 results (PR/Presentation/non-GAAP recs/Earnings supplement/10-Q) came in above expectations with notable performance in bioprocessing, while 2025 topline guidance was reiterated and bottom line guidance initiated bracketing the Street. 1Q non-GAAP core revenue growth was flat (vs. Street of -2.3% and guide of -LSD) as bioprocessing revenue grew +HSD in 1Q (consumables +LDD) with... More
